DAVID GREENE, HOST:
Many Americans 65 and older are familiar with Medicare Part D. It helps seniors with the cost of prescription drugs. The nonprofit news organization ProPublica has a story out today, detailing how vulnerable this program is to fraudulent spending and how little the federal government's doing to stop it.
ProPublica's Tracy Weber was the lead reporter.
So, your story takes us back to 2006, when Medicare part D was first being rolled out. And you quote a law enforcement official in Los Angeles as saying "let the crime spree begin." What did he see about this program that early on?
TRACY WEBER: Well, part D wasn't set up to look at what the doctors were doing. It was set up to get seniors and the disabled their prescriptions as quickly as possible. It wasn't sort of set up to have any safeguards against fraud in it. And investigators, when they heard about the program, they knew immediately that it would be vulnerable.
GREENE: They saw a program where speed was the priority. I mean, let's get this money and get these seniors the drugs and the help that they need as fast as possible, and not worry about what could be going wrong.
WEBER: Right. And most private insurers have about a month to pay a claim for a drug. But in Part D, it's 14 days, and it's a so-called pay-and-chase. You pay the claim, and then if there's a problem with it, you try to and investigate it and get your money back. But, as anyone knows, with scams, it's going to be really hard to get your money back after you've already paid it.
GREENE: What are some of the actual schemes that you've uncovered?
WEBER: Well, we got onto this when we called up a psychiatrist in Los Angeles. And he was prescribing massive amounts of really expensive brand name drugs, and drugs that a psychiatrist wouldn't normally prescribe, like asthma drugs. And we called him up, because in 2010, he had written $3.8 million worth of these drugs. And he said: I didn't write any of those drugs. And it turns out that he had gotten involved with a clinic where they call, you know, asked him, hey, we'll set you up in this clinic. You'll just come and see patients. We'll take care of the billing, and you just get paid when we get paid.
And, apparently, what investigators told him is they took his identification. They had prescription pads, everything, and started writing bogus prescriptions on his identification. And what was really interesting is once I started poking around in his case, investigators all along the way had known, but no one had stopped or blocked his number to stop the fraud from going on.
GREENE: So, can you give me some of the reasons why federal oversight is so ineffective?
WEBER: Well, when we took a look at where cases go - like, let's say, for instance, private insurers spot something they consider to be fraudulent and...
GREENE: And we should say private companies are managing this program for the federal government.
WEBER: Right. And they take these tips, and they send them on to Medicare's fraud contractor, known as the Medic. The Medic then sort of investigates the case, looks at the doctors prescribing across plans, and then refers those cases to the inspector general, which investigates them. But only a tiny percentage of the cases that the Medic looks at get referred. Just 12 percent of the cases from April 2010 to March 2011 were referred on to the inspector general.
GREENE: The rest fell off somewhere along the way.
WEBER: Right. And the insurers tell us they never hear back, and they just disappear. Everyone points to resources. U.S. attorneys can make whatever they want a priority, and if health care fraud is not a priority, the cases will not get prosecuted. But many people believe that Medicare - the investigators we talk to, the insurers - should take some steps to be able to block a doctor's ID number if they believe it's involved in fraud, or else give the doctor a new identification number to prevent further fraud from going on.
GREENE: I get the sense from your story that federal officials were not all that willing to play ball when you went to them as you were doing your reporting. But I guess I just wonder, we're talking about a $67 billion program here, and some of these schemes are in the hundreds of thousands, maybe a couple million dollars. Is it possible that they've just decided that, given the relative small amounts of money, it's just not worth paying to enforce this strictly?
WEBER: That could be true. We asked a series of detailed questions of Medicare about this and, you know, what they do to pursue it, and they gave us a paragraph response, and basically said they can take it seriously and refer cases to law enforcement. But it could very well be that on a scale of what they consider to be relevant, this doesn't rise to something they want to pursue.
GREENE: Tracy Weber, thanks so much for talking to us.
WEBER: Thank you.
NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR’s programming is the audio.